These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 18539314)

  • 21. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.
    Cho SM; Ha HK; Byun JY; Lee JM; Kim CJ; Nam-Koong SE; Lee JM
    AJR Am J Roentgenol; 2002 Aug; 179(2):391-5. PubMed ID: 12130439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study.
    Signorelli M; Guerra L; Pirovano C; Crivellaro C; Fruscio R; Buda A; Cuzzucrea M; Elisei F; Ceppi L; Messa C
    Gynecol Oncol; 2013 Nov; 131(2):395-9. PubMed ID: 23988414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.
    Risum S; Høgdall C; Markova E; Berthelsen AK; Loft A; Jensen F; Høgdall E; Roed H; Engelholm SA
    Int J Gynecol Cancer; 2009 May; 19(4):600-4. PubMed ID: 19509556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac.
    Díaz-Montes TP; Jacene HA; Wahl RL; Bristow RE
    Gynecol Oncol; 2005 Sep; 98(3):510-2. PubMed ID: 15992914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET-Probe: Evaluation of Technical Performance and Clinical Utility of a Handheld High-Energy Gamma Probe in Oncologic Surgery.
    Gulec SA; Daghighian F; Essner R
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):9020-9027. PubMed ID: 16865592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
    Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
    Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
    Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
    Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
    Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
    Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.
    Hynninen J; Auranen A; Carpén O; Dean K; Seppänen M; Kemppainen J; Lavonius M; Lisinen I; Virtanen J; Grénman S
    Gynecol Oncol; 2012 Jul; 126(1):64-8. PubMed ID: 22542580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [PET/CT-guided salvage surgery protocol. Results with ROLL Technique and PET probe].
    García JR; Fraile M; Soler M; Bechini J; Ayuso JR; Lomeña F
    Rev Esp Med Nucl; 2011; 30(4):217-22. PubMed ID: 21514975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.
    Picchio M; Sironi S; Messa C; Mangili G; Landoni C; Gianolli L; Zangheri B; Viganò R; Aletti G; De Marzi P; De Cobelli F; Del Maschio A; Ferrari A; Fazio F
    Q J Nucl Med; 2003 Jun; 47(2):77-84. PubMed ID: 12865867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma].
    Grabiec M; Walentowicz M; Nowicki P
    Ginekol Pol; 2006 Oct; 77(10):746-52. PubMed ID: 17219805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer.
    Dauwen H; Van Calster B; Deroose CM; Op de Beeck K; Amant F; Neven P; Berteloot P; Leunen K; Timmerman D; Vergote I
    Gynecol Oncol; 2013 Dec; 131(3):694-700. PubMed ID: 23988417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer.
    Drieskens O; Stroobants S; Gysen M; Vandenbosch G; Mortelmans L; Vergote I
    Gynecol Obstet Invest; 2003; 55(3):130-4. PubMed ID: 12865590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.
    Peng P; Zhu ZH; Zhong ZJ; Zheng K; Yang JX; Cao DY; Shen K
    Br J Radiol; 2015 Aug; 88(1052):20150109. PubMed ID: 25989698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rectal lymph node metastasis in recurrent ovarian carcinoma: essential role of 18F-FDG PET/CT in treatment planning.
    Kumagai K; Okamura T; Toyoda M; Senzaki H; Watanabe C; Ohmichi M
    World J Surg Oncol; 2013 Aug; 11(1):184. PubMed ID: 23938043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.